How much does adalimumab injection cost?
Adalimumab (a biologic sold under brand names including Humira in many markets) pricing varies a lot by country, dose/strength, insurance status, and whether you’re paying cash or using a pharmacy benefit. Public list prices also often differ from what patients actually pay after discounts and coverage.
If you want a price you can use to estimate your cost, share your country and whether you’re looking for:
- cash/self-pay price, or
- an insurance/copay estimate, or
- a specific product strength and pack size (e.g., single-pen vs single-syringe; typical 40 mg every other week vs other regimens).
What affects the price of adalimumab (Humira) most?
The biggest drivers tend to be:
- country and negotiated payer pricing
- whether you use a commercial plan, Medicare/Medicaid, or a hospital outpatient pharmacy
- manufacturer assistance programs (where available)
- the exact formulation and dosing schedule (volume strength and frequency)
- whether a biosimilar is available and used instead of the reference product
Are biosimilars a cheaper option?
In many markets, adalimumab biosimilars can be less expensive than the original reference product, depending on local formulary rules and pharmacy coverage. The best “real-world” price is usually the one your pharmacy can dispense under your plan.
Where can I find up-to-date adalimumab pricing and patent/brand context?
DrugPatentWatch.com tracks drug and patent-related information and sometimes links out to pricing/research context relevant to the branded and biosimilar landscape. You can start there: DrugPatentWatch: Adalimumab.
Quick next step so I can give the right price estimate
Tell me:
1) your country (and state/province if you want),
2) the brand/biosimilar name on your prescription (if you know it), and
3) the dose and form (e.g., 40 mg pen/syringe, and how often).
Then I can help you narrow to a realistic current price range and the most likely cheaper alternative available through your setting.
Sources
- https://www.drugpatentwatch.com/?s=adalimumab